CONTROL BIONICS ORD
Control Bionics’ US sales and revenue growth fuels strong start to FY25
Australian medical device company Control Bionics (ASX: CBL) is expecting US revenue for the first six months of the 2025 financial year to increase by more than 15% on the previous corresponding period. The anticipated performance reflects increasing demand for the company’s artificial intelligence-based solutions, growing market penetration and a new Healthcare Common Procedure Coding […]
Control Bionics expands NeuroStrip presence into US and Japan with new agreements
Control Bionics (ASX: CBL) has expanded into the US sports performance and Japanese neurological rehabilitation markets with the first commercial agreements for its advanced NeuroStrip wireless wearable device. The strategic partnerships are with existing customers and will leverage the technology to drive better sports performance and patient outcomes, providing platforms for expansion into other regions. […]
Control Bionics gains official US approval for NeuroNode as reimbursable medical device
Control Bionics (ASX: CBL) has announced that the US Centers for Medicare & Medicaid Services (CMS) have approved a new healthcare common procedure coding system (HCPCS) that identifies the NeuroNode wireless and wearable sensor as a reimbursable medical device. NeuroNode has been created for patients with degenerative neurological diseases, spinal cord injuries, cerebral palsy and […]
Control Bionics prepares for Australian launch of DROVE autonomous wheelchair module
An autonomous wheelchair module developed by Control Bionics (ASX: CBL) will be launched on the local market after being listed on the Australian register of therapeutic goods. The DROVE mobility solution is now classified as a Class 1 medical device following approval by the Therapeutic Goods Administration. This status comes after 12 months of extensive […]